You are viewing: Mexico AI in Oncology Market analysis
Part of: AI in Oncology Market (Global)

The Mexico AI in Oncology Market was valued at $22.8 Million in 2024 and projected to reach to $101.1 Million by 2029, representing a compound annual growth rate of 28.2%. Mexico's AI in Oncology market is positioned for exceptional growth through 2029, driven by increasing cancer prevalence, healthcare infrastructure investments, and adoption of advanced diagnostic technologies.

Mexico AI in Oncology Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Mexico AI in Oncology Market Trends and Insights

  • This represents a compound annual growth rate of 28.2%, reflecting Mexico's increasing adoption of artificial intelligence technologies in cancer diagnosis, treatment planning, and patient management.
  • Mexico's healthcare sector is leveraging AI-driven oncology solutions to improve clinical outcomes and operational efficiency across both public and private institutions. The growth trajectory in Mexico is driven by rising cancer incidence, improved healthcare infrastructure investment, and growing partnerships between Mexican medical centers and global AI technology providers.
  • Mexico's position as a regional healthcare hub in Latin America is accelerating the integration of advanced AI tools in oncology departments.
  • By 2029, Mexico is expected to establish itself as a key market for AI-enabled cancer care solutions, with significant opportunities for diagnostic imaging AI, predictive analytics, and personalized treatment platforms..

Key Market Statistics

  • CAGR (2024-2029) 28.2% CAGR
  • Market Size, 2024 ~USD 22.8 Million
  • Forecast, 2029 ~USD 101.1 Million
  • Country Mexico

Mexico AI in Oncology Market Overview

Rapid Market Expansion :

Mexico's AI in Oncology market is growing at 28.2% CAGR, nearly matching the global rate of 29.4%, demonstrating strong regional adoption and investment in cancer care technologies.

Significant Revenue Growth :

Market valuation is projected to grow from $22.8 million in 2024 to $101.1 million by 2029, representing a 343% increase over five years and indicating substantial healthcare modernization.

AI-Driven Cancer Care Innovation :

Mexican healthcare institutions are increasingly implementing AI solutions for diagnostic imaging, treatment planning, and personalized oncology protocols, improving patient outcomes and operational efficiency.

Healthcare Sector Modernization :

Mexico's oncology sector is leveraging AI technologies to address cancer diagnosis challenges, optimize treatment pathways, and enhance patient management across public and private healthcare systems.

Mexico AI in Oncology Market Dynamics

  • The 28.2% CAGR reflects growing recognition among Mexican healthcare providers of AI's potential to improve oncological outcomes and operational efficiency.
  • Government healthcare initiatives and private sector investments are accelerating the integration of AI-powered solutions in major medical centers and hospitals.
  • By 2029, Mexico is expected to establish itself as a regional leader in AI-driven cancer care, with expanded access to intelligent diagnostic and treatment planning tools across urban and emerging healthcare markets..

Related Ecosystem

Healthcare Analytics

Top Technologies
  • Machine Learning
  • Natural Language Processing (NLP)
  • Blood Pressure Monitors
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
Top Companies
  • Oracle Corporation
  • PHILIPS HEALTHCARE
  • Siemens healthineers
  • Zensar Technologies Limited
  • EPIC SYSTEMS CORPORATION

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Key Takeaways

      • Mexico's AI in Oncology market is valued at $22.8 million in 2024 and is forecast to grow to $101.1 million by 2029, representing a 28.2% CAGR.
      • Mexico is leveraging AI technologies for improved cancer diagnosis, treatment planning, and patient outcomes across public and private healthcare institutions.
      • Rising cancer incidence and healthcare infrastructure investments are primary drivers accelerating AI adoption in Mexico's oncology sector.
      • Mexico's role as a regional healthcare leader in Latin America positions it as a strategic market for AI-enabled oncology solutions through 2029.

      AI in Oncology Market Report Scope

      Report Metric Details
      Base Year 2024
      Fastest Growing Segment DEEP LEARNING (Type)
      Forecast Period 2024-2029
      Growth Rate CAGR of 29.4% from 2024 to 2029
      Largest Segment SOLID TUMORS (Cancer Type)
      Market Size Base Year (Billions) ~USD 2.45 (2024)
      Revenue Forecast (Billions) ~USD 8.9 (2029)
      Segments Covered Technology, Type, Application, Cancer Type, End User, Player Type, Deployment Model

      Mexico AI in Oncology Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Technology

      • Computer Vision
      • Context-Aware Processing & Computing
      • Image Analysis
      • Machine Learning
      • Natural Language Processing
      • Natural Language Processing (Nlp)

      By Type

      • Adaptive Trial Design & Monitoring
      • AI-Guided Drug Delivery
      • Brain Tumors
      • Breast Cancer
      • Candidate Selection & Validation
      • Chemotherapy
      • Clinical Trial Optimization
      • Colorectal Cancer
      • Combination & Dose Optimization
      • Computed Tomography
      • Computed Tomography (Ct)
      • Deep Learning
      • Digital Pathology & Histopathology
      • Genetic Risk Prediction
      • Hit Identification & Prioritization
      • Hit-To-Lead Identification/Lead Generation
      • Hospitals & Clinics
      • Imaging & Radiology
      • Immunotherapy
      • Intraoperative Guidance & Robotics
      • Intraoperative Guidance And Robotics
      • Laboratories & Diagnostic Centers
      • Lead Optimization
      • Leukemia
      • Liquid Biopsy & Biomarker Detection
      • Long-Term Prediction
      • Lung Cancer
      • Lymphoma
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mental Health & Support Systems
      • Multiple Myeloma
      • Nuclear Imaging
      • Other Healthcare Providers
      • Other Hematologic Malignancies
      • Other Hematological Malignancies
      • Other Imaging Modalities
      • Other Machine Learning Technologies
      • Other Solid Tumors
      • Other Tumors
      • Others Healthcare Providers
      • Patient Education & Empowerment
      • Personalized Treatment Planning
      • Postoperative Analysis & Recovery
      • Precision Medicine & Genomic Analysis
      • Preclinical Testing
      • Predictive Modeling For Human Trials
      • Predictive Modelling For Human Trials
      • Predictive Models For Treatment Response
      • Preoperative Imaging & 3D Modeling
      • Preoperative Imaging And 3D Modeling
      • Prostate Cancer
      • Radiation Therapy
      • Radiomics & Radiogenomics
      • Radiomics And Radiogenomics
      • Recurrence Monitoring
      • Reinforcement Learning
      • Remote Patient Monitoring
      • Specialty Centers
      • Supervised Learning
      • Surgical Planning & Assistance
      • Symptom Management & Virtual Assistance
      • Target Identification & Validation
      • Targeted Therapy
      • Treatment Recommendation Systems
      • Ultrasound
      • Unsupervised Learning
      • X-Ray Imaging

      By Application

      • Data Management & Analytics
      • Diagnosis & Early Detection
      • Drug Development
      • Drug Discovery
      • Other Applications
      • Patient Engagement & Remote Monitoring
      • Post Treatment Surveillance & Survivorship Care
      • Post-Treatment Surveillance & Survivorship Care
      • Treatment Planning & Personalization

      By Cancer Type

      • Hematologic Malignancies
      • Hematological Malignancies
      • Other Cancer Types
      • Other Cancers
      • Others Cancer Types
      • Solid Tumors

      By End User

      • Academic & Research Institutions
      • Government & Regulatory Agencies
      • Healthcare Payers
      • Healthcare Providers
      • Medical Device/ Equipment Companies
      • Medical Device/Equipment Companies
      • Other End Users
      • Pharmaceutical & Biotechnology Companies

      By Player Type

      • Business Process Service Providers
      • Integrated Suite/Platform Providers
      • Niche/Point Solution Providers
      • Technology Providers

      By Deployment Model

      • Cloud-Based Model
      • Hybrid Model
      • On-Premises Model

      MEXICO: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030

      Segment202220232024202520262027202820292030CAGR (%)
      ACADEMIC & RESEARCH INSTITUTIONS1.461.922.433.083.9256.48.2210.5927.8
      GOVERNMENT & REGULATORY AGENCIES0.570.740.921.151.441.812.292.893.6726
      HEALTHCARE PAYERS0.360.480.60.760.961.221.551.992.5527.3
      HEALTHCARE PROVIDERS6.348.3910.6913.6717.5322.5629.1137.6948.9228.9
      MEDICAL DEVICE/EQUIPMENT COMPANIES1.261.632.042.573.234.085.186.588.3926.5
      OTHER END USERS0.30.390.50.620.790.991.251.58226.1
      PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES3.334.395.587.119.0811.6314.9619.2924.9328.3
      TOTAL13.6217.9422.7528.9536.9547.360.7478.25101.0628.2

      Target Audience

      • Healthcare Technology Vendors : AI software and medical device companies need Mexico-specific market data to develop localized solutions, understand adoption barriers, and establish distribution channels in this high-growth oncology market.
      • Hospital and Clinic Networks : Mexican healthcare providers require market intelligence to evaluate AI oncology investments, benchmark against peers, and make procurement decisions aligned with patient care improvements and operational efficiency.
      • Private Equity and Venture Capital : Investment firms targeting Mexico's healthcare sector need validated market sizing and growth projections to identify promising AI oncology startups and healthcare technology companies for funding.
      • Government and Health Policy Makers : Mexican health ministry officials and policy advisors use market data to inform healthcare technology adoption strategies, budget allocation, and regulatory frameworks supporting AI integration in oncology.
      • Pharmaceutical and Biotech Companies : Oncology-focused pharmaceutical firms need Mexico market insights to align AI diagnostic tools with drug development pipelines and identify opportunities for companion diagnostic partnerships.

      Reasons to Buy this Report

      • Market Entry Strategy : Comprehensive Mexico-specific data enables healthcare companies and AI vendors to develop targeted market entry strategies, identify key stakeholders, and prioritize investment in high-growth oncology segments.
      • Competitive Intelligence : Detailed insights into Mexico's AI adoption patterns, technology preferences, and healthcare provider requirements provide competitive advantages for positioning products and services in this emerging market.
      • Investment Decision Support : Validated market projections and growth metrics for Mexico enable investors and healthcare funds to make informed decisions about capital allocation in the region's oncology technology sector.
      • Partnership Identification : Mexico-focused market analysis helps identify potential distribution partners, hospital networks, and healthcare institutions actively adopting AI oncology solutions for strategic collaborations.
      • Regulatory and Operational Insights : Country-specific data addresses Mexico's unique healthcare regulations, reimbursement models, and operational requirements essential for successful market penetration and sustainable business growth.

      Frequently asked questions

      What is the current size of Mexico's AI in Oncology market?

      Mexico's AI in Oncology market was valued at $22.8 million in 2024 and is expected to grow significantly through the forecast period.

      What is the projected market size for Mexico's AI in Oncology sector by 2029?

      Mexico's AI in Oncology market is projected to reach $101.1 million by 2029, driven by increased adoption and healthcare investments.

      What is the growth rate of Mexico's AI in Oncology market?

      Mexico's AI in Oncology market is growing at a compound annual growth rate (CAGR) of 28.2% from 2024 to 2029.

      What factors are driving AI adoption in Mexico's oncology sector?

      Key drivers include rising cancer incidence, healthcare infrastructure improvements, partnerships with global AI providers, and the need for better clinical outcomes in Mexico.

      How does Mexico's AI in Oncology market compare to other Latin American countries?

      Mexico is positioned as a regional healthcare hub in Latin America, with strong infrastructure and investment supporting faster AI adoption in oncology compared to many neighboring markets.

      RESEARCH METHODOLOGY

      The study involved significant activities to estimate the current size of the AI in oncology. Exhaustive secondary research was done to collect information on the AI in oncology market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in oncology market.

      Secondary Research

      This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in oncology solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

      Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in oncology vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

      Primary Research

      In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in oncology market.

      After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in oncology solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

      In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

      Breakdown of Primary Participants:

      AI in Oncology Market

      Note 1: Others include sales managers, marketing managers, and product managers.

      Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in oncology. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry and markets have been identified through extensive secondary research.
      • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
      AI in Oncology Market

      Data Triangulation

      After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      AI I in oncology is the utilization of AI tools such as machine learning, natural language processing, and computer vision, among others to analyze genomic data and large gene mutations that are unique to an individual’s cancer profile. These AI tools are adopted by various end-users including labs, research centers, hospitals, and biotechnology & pharmaceuticals, among others to address the global cancer burden and the need for precision medicine in oncology.

      Further, AI boosts the speed and accuracy of cancer diagnosis and screening. The major developments include:

      • Pathologists can detect malignancy in prostate biopsy photos with the help of FDA-approved AI software.
      • AI quickly analyzes medical pictures, such as mammograms, increasing radiologists' productivity and enhancing risk assessment and detection of breast cancer.
      • Deep learning is used by NCI scientists to automatically detect precancerous cervical lesions as part of their efforts to improve cervical and prostate cancer screening.

      Stakeholders

      • Clinical/Physician Centers
      • AI Providers
      • Clinical Research Organizations
      • Pharmaceutical/Biopharmaceutical Companies
      • Research and Development (R&D) Companies
      • Business Research and Consulting Service Providers
      • Medical Research Laboratories
      • Academic Medical Centers/Universities/Hospitals
      • Government Agencies
      • Regulatory Agencies
      • Clinical Researchers
      • Clinical Research Organizations
      • Accountable Care Organizations
      • Investors and Venture Capitalists

      Report Objectives

      • To define, describe, and forecast the AI in oncology market based on player type, application, cancer type, technology, deployment model, end user, and region
      • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
      • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
      • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
      • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
      • To profile the key players and comprehensively analyze their market sizes and core competencies
      • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally

      Get the Full AI in Oncology Market Report

      Full forecast, segment splits, and company analysis for all AI in Oncology Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status